PDCD1 and breast carcinoma: For example, the combination of anti-PD-1 and/or anti-LAG-3 mAbs with IL-12, which promotes NK cell recruitment and activation, significantly enhanced the anti-metastatic effect that entirely depended on NK cells in breast cancer (95).